Skip to search formSkip to main contentSkip to account menu

sabarubicin

Known as: 4-demethoxy-7-O-(2,6-dideoxy-4-O-(2,3,6-trideoxy-3-amino-alpha-L-lyxo-hexopyranosyl)-alpha-L-lyxo-hexopyranosyl)-adriamycinone 
A disaccharide analogue of the anthracycline antineoplastic antibiotic doxorubicin. Sabarubicin intercalates into DNA and interacts with… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

DisaccharidesDoxorubicin

Narrower (1)

MEN 10755

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive…
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG… 
2008
2008
Phase II study of sabarubicin (MEN 10755) in newly diagnosed patients with extensive stage small cell lung cancer (ESCLC): Final report
19043 Background: Despite being sensitive to cytotoxic chemotherapeutic agents and the recent development of effective novel… 
2007
2007
Sabarubicin (MEN10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells.
BACKGROUND The role of mitochondrial DNA (mtDNA) in anthracycline-induced apoptosis is controversial. Sabarubicin accumulates in… 
Review
2006
Review
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2005
2005
Sabarubicin- (MEN 10755) and paclitaxel show different kinetics in nuclear factor-kappaB (NF-kB) activation: effect of parthenolide on their cytotoxicity.
BACKGROUND Several antitumor drugs have been described to induce nuclear factor kappaB (NF-kappaB), but results about its role in… 
2005
2005
NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780.
The development of chemoresistance is a major obstacle for successful anticancer therapy. Understanding the molecular mechanisms… 
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)